KR20200020405A - Composition for improving skin wrinkle comprising plant extract - Google Patents
Composition for improving skin wrinkle comprising plant extract Download PDFInfo
- Publication number
- KR20200020405A KR20200020405A KR1020180096087A KR20180096087A KR20200020405A KR 20200020405 A KR20200020405 A KR 20200020405A KR 1020180096087 A KR1020180096087 A KR 1020180096087A KR 20180096087 A KR20180096087 A KR 20180096087A KR 20200020405 A KR20200020405 A KR 20200020405A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- group
- composition
- present
- plant
- Prior art date
Links
- 239000000419 plant extract Substances 0.000 title claims abstract description 59
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 230000037303 wrinkles Effects 0.000 title claims abstract description 33
- 239000000284 extract Substances 0.000 claims abstract description 104
- 229940069445 licorice extract Drugs 0.000 claims abstract description 24
- 239000004480 active ingredient Substances 0.000 claims abstract description 17
- 235000020708 ginger extract Nutrition 0.000 claims abstract description 16
- 229940002508 ginger extract Drugs 0.000 claims abstract description 16
- 241000132536 Cirsium Species 0.000 claims description 26
- 239000002537 cosmetic Substances 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 19
- -1 packs Substances 0.000 claims description 19
- 240000002913 Trifolium pratense Species 0.000 claims description 17
- 235000015724 Trifolium pratense Nutrition 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 17
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 239000006071 cream Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 235000013402 health food Nutrition 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 8
- 230000006872 improvement Effects 0.000 claims description 8
- 239000006210 lotion Substances 0.000 claims description 8
- 239000000499 gel Substances 0.000 claims description 7
- 239000002674 ointment Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 229910001868 water Inorganic materials 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 3
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
- 239000000686 essence Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000003491 skin Anatomy 0.000 abstract description 47
- 102000004237 Decorin Human genes 0.000 abstract description 37
- 108090000738 Decorin Proteins 0.000 abstract description 37
- 102000004169 proteins and genes Human genes 0.000 abstract description 13
- 108090000623 proteins and genes Proteins 0.000 abstract description 13
- 102000004954 Biglycan Human genes 0.000 abstract description 9
- 108090001138 Biglycan Proteins 0.000 abstract description 9
- 229920002683 Glycosaminoglycan Polymers 0.000 abstract description 7
- 210000004207 dermis Anatomy 0.000 abstract description 7
- 244000272459 Silybum marianum Species 0.000 abstract 1
- 235000010841 Silybum marianum Nutrition 0.000 abstract 1
- 235000020228 cimicifuga racemosa extract Nutrition 0.000 abstract 1
- 229940059483 trifolium pratense flower extract Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 31
- 230000001965 increasing effect Effects 0.000 description 22
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 16
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 16
- 102000008186 Collagen Human genes 0.000 description 12
- 108010035532 Collagen Proteins 0.000 description 12
- 229920001436 collagen Polymers 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 239000002994 raw material Substances 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 210000002950 fibroblast Anatomy 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 8
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 7
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 6
- 210000004177 elastic tissue Anatomy 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 5
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000003796 beauty Effects 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000009759 skin aging Effects 0.000 description 4
- 210000001626 skin fibroblast Anatomy 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000004264 Petrolatum Substances 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 102000004243 Tubulin Human genes 0.000 description 3
- 108090000704 Tubulin Proteins 0.000 description 3
- 229960000458 allantoin Drugs 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 235000015927 pasta Nutrition 0.000 description 3
- 229940066842 petrolatum Drugs 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000037394 skin elasticity Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000202807 Glycyrrhiza Species 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- 206010027304 Menopausal symptoms Diseases 0.000 description 2
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229940081733 cetearyl alcohol Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 2
- 229960004245 silymarin Drugs 0.000 description 2
- 235000017700 silymarin Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000694589 Gesneria viridiflora Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019493 Macadamia oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 241000208422 Rhododendron Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 241000234314 Zingiber Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000036569 collagen breakdown Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 125000003450 decanoic acid ester group Chemical group 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000002849 elastaseinhibitory effect Effects 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 1
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 1
- 235000002780 gingerol Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- JQOAQUXIUNVRQW-UHFFFAOYSA-N hexane Chemical compound CCCCCC.CCCCCC JQOAQUXIUNVRQW-UHFFFAOYSA-N 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229940100554 isononyl isononanoate Drugs 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000010469 macadamia oil Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Description
본 발명은 피부 주름 개선용 조성물에 관한 것으로서, 보다 상세하게는 진피의 기질 단백질인 데코린(Decorin)과 바이글리칸(Biglycan)의 발현을 증가시키거나 이들에 결합해 있는 글리코사미노글리칸의 사슬의 길이를 증가시킴으로써 피부 주름을 개선하고 탄력을 향상시킬 수 있는 식물 추출물을 유효성분으로 함유하는 피부 주름 개선용 조성물에 관한 것이다.The present invention relates to a composition for improving skin wrinkles, and more particularly, to the expression of glycosaminoglycans that increase or bind the expression of decorin and biglycan, which are substrate proteins of the dermis. It relates to a composition for improving skin wrinkles containing a plant extract as an active ingredient that can improve skin wrinkles and improve elasticity by increasing the length of the chain.
피부는 가장 넓은 신체 조직으로 외부환경과 자극으로부터 1차적으로 접촉을 하는 기관으로써, 외부 물질과 자극에 대한 최초의 방어기관으로 작용을 할 뿐 아니라 체온 및 체내 수분을 조절하는 신체 내 신진대사에도 매우 중요한 역할을 한다. 또한, 피부는 외부로 보여지는 첫 번째 기관이기 때문에 외적인 아름다움 표현하는 매우 중요한 기관이기도 하다. 이러한 외적인 아름다움은 현대사회에 들어서 건강을 생각하는 것과 유사하게 작용하고 있는 추세이다.The skin is the largest body tissue that is the primary contact with the external environment and stimuli. It acts as the first defense against external substances and stimuli, as well as for metabolism in the body that regulates body temperature and body moisture. Plays an important role. Also, since the skin is the first organ to be seen from the outside, it is also a very important organ for expressing external beauty. This external beauty tends to behave similarly to health in modern society.
노령인구수가 증가함에 외모의 아름다움이 젊음과 건강을 상징하는 판단의 기준으로 자리잡을 뿐만 아니라 젊은 층의 사람에게 있어서는 이러한 외적인 아름다움이 자신감으로 표출로 드러나게 되고, 본인의 업무능력에 영향을 주는 경쟁력으로 자리잡고 있기 때문이다. 이러한 이유로 학문적, 산업적인 측면에서 피부 노화 및 피부 주름을 억제하기 위한 노력이 활발히 이루어지고 있다.As the number of older people increases, not only does beauty of appearance become the standard of judgment that symbolizes youth and health, but also for the younger people, this external beauty is revealed as confidence and the competitiveness that affects their work ability. Because it is located. For this reason, efforts are being actively made to suppress skin aging and wrinkles on the academic and industrial sides.
이러한 피부노화의 주된 외관적인 변화는 주름과 피부탄력의 저하로서, 진피의 구조적인 변화에 기인한 것으로 알려져 있다. 진피는 피부의 최외각인 표피의 아래 존재하는 피부의 구조로 콜라겐과 탄력 섬유가 구성성분으로써 가장 많은 비중을 차지한다. 이러한 콜라겐과 탄력 섬유가 피부탄력을 유지하는데 중요한 역할을 한다. 조직학적으로 노화된 피부의 진피는 콜라겐 섬유의 굵기가 감소하고, 배열도 엉성해지며, 탄력섬유의 복잡하고 정교한 결합이 끊어져 있다. 이러한 현상은 지속적인 자외선 노출에 따른 콜라겐과 탄력섬유 분해효소의 발현이 그 이유이며 노인 피부의 주름 형성에 가장 주된 원인이다(특허문헌 1).The major change in skin aging is a decrease in wrinkles and skin elasticity, which is known to be due to structural changes in the dermis. The dermis is the structure of the skin below the epidermis, the outermost part of the skin, and collagen and elastic fibers make up the largest portion as a component. These collagen and elastic fibers play an important role in maintaining skin elasticity. The dermis of histologically aged skin is reduced in the thickness of the collagen fibers, the arrangement is poor, and the complex and sophisticated bonding of the elastic fibers is broken. This phenomenon is due to the expression of collagen and elastic fiber degrading enzymes due to continuous UV exposure, and is the main cause for wrinkle formation of elderly skin (Patent Document 1).
피부 주름을 개선하기 위한 기능성 화장품의 개발은 콜라겐의 분해를 촉진하는 MMP(Matrix Metalloproteinase)-1과 같은 효소들의 억제와 핵심 기질단백질인 콜라겐의 발현 증가를 중심으로 이루어져 왔으나, 실질적으로 만족스러운 효과를 보이는 기능성 화장품의 개발은 아직 요원하다. 유효한 효과를 보이는 것으로 알려진 레티노익 산이나 레티놀과 같은 성분들이 알려져 있으나, 레티노익 산의 경우에는 강한 부작용이 나타나며, 레티놀의 경우에는 비교적 부작용은 약하나 역시 부작용이 나타날 수 있으며, 안정성이 약해서 활성이 쉽게 약해지는 등의 여러 가지 문제점들을 가지고 있다.The development of functional cosmetics to improve skin wrinkles has been focused on the inhibition of enzymes such as matrix metalloproteinase (MMP) -1, which promotes the breakdown of collagen, and the increase of the expression of collagen, a key substrate protein, but it has practically satisfactory effects. The development of visible functional cosmetics is still a long way off. Ingredients such as retinoic acid and retinol are known to have an effective effect, but retinoic acid has strong side effects, and retinol has relatively low side effects but also side effects, and stability is weak, so it is easy to be active. There are various problems such as weakening.
상기 MMP는 진피층의 콜라겐 붕괴에 결정적인 영향을 미치는 인자로서, MMP의 발현 또는 활성 억제를 통한 피부 주름 개선에 관해 많은 연구가 이루어지고 있다. 활성화된 MMP는 2-마크로글로불린(Macroglobulin)이나 TIMP(Tissue Inhibitors of Metalloproteinase)와 같은 저해제에 의해 활성이 조절되며, 피부의 각질형성세포, 섬유아세포를 포함하는 대다수의 많은 세포들이 MMP를 분비한다(비특허문헌 1). 단 한번의 자외선 조사에도 피부 내의 MMP 활성이 증가되어 피부 내의 콜라겐을 현저하게 붕괴시키므로, MMP는 피부 주름의 형성에 있어서 매우 중요한 역할을 한다. 그러나, 콜라겐 이외의 다른 진피 단백질의 발현 증가를 통한 피부 주름 개선에 대해서는 선행 연구가 거의 없는 실정이다.The MMP is a determinant factor in collagen breakdown of the dermal layer, and many studies have been conducted to improve skin wrinkles by inhibiting the expression or activity of MMP. Activated MMPs are regulated by inhibitors such as 2-macroglobulin or tissue inhibitors of metalloproteinases (TIMPs), and many cells, including keratinocytes and fibroblasts in the skin, secrete MMPs ( Non-Patent Document 1). MMPs play a very important role in the formation of skin wrinkles because even once UV irradiation increases MMP activity in the skin and significantly disrupts collagen in the skin. However, there is little prior research on improving skin wrinkles by increasing expression of dermal proteins other than collagen.
본 발명은 우수한 데코린 및 바이글리칸 발현 증가 활성을 통한 피부 탄력도 개선 효과 및 피부 주름 개선 효과를 갖는 식물 추출물을 유효성분으로 함유하는 피부 주름 개선용 조성물을 제공하는 것을 목적으로 한다.It is an object of the present invention to provide a composition for improving skin wrinkles, which contains a plant extract having an effect of improving skin elasticity and improving skin wrinkles through an excellent activity of decorin and biglycan expression.
상기 목적을 달성하기 위하여, 본 발명은 흰무늬엉겅퀴 추출물, 생강 추출물, 유럽승마 추출물, 감초 추출물 및 붉은토끼풀꽃 추출물로 이루어진 군으로부터 선택되는 2종 이상의 식물 추출물을 유효성분으로 함유하는 피부 주름 개선용 화장료 조성물을 제공한다.In order to achieve the above object, the present invention for improving skin wrinkles containing two or more plant extracts selected from the group consisting of white thistle extract, ginger extract, European horse riding extract, licorice extract and red shamrock extract as an active ingredient It provides a cosmetic composition.
본 발명의 한 구현예에 따르면, 상기 식물 추출물의 제조에 사용되는 추출용매는 물, 유기용매 또는 이들의 혼합물일 수 있고, 상기 유기용매는 알코올, 헥산, 에테르, 글리세롤, 프로필렌글리콜, 부틸렌글리콜, 에틸아세테이트, 메틸아세테이트, 디클로로메탄, 클로로포름, 벤젠, 또는 이들의 혼합용매일 수 있으나 이에 한정되는 것은 아니다. 본 발명의 바람직한 구현예에 따르면, 상기 알코올은 저급 알코올, 예컨대 메탄올, 에탄올, 프로판올 또는 부탄올일 수 있으나 이에 한정되는 것은 아니다.According to one embodiment of the invention, the extraction solvent used in the preparation of the plant extract may be water, an organic solvent or a mixture thereof, the organic solvent is alcohol, hexane, ether, glycerol, propylene glycol, butylene glycol , Ethyl acetate, methyl acetate, dichloromethane, chloroform, benzene, or a mixed solvent thereof, but is not limited thereto. According to a preferred embodiment of the present invention, the alcohol may be a lower alcohol, such as methanol, ethanol, propanol or butanol, but is not limited thereto.
본 발명의 한 구현예에 따르면, 본 발명의 화장료 조성물은 유연화장수, 영양화장수, 에센스, 로션, 영양크림, 마사지크림, 팩, 젤, 연고, 패취, 분무제, 리니먼트제, 파스타아제, 카타플라스마제 등의 제형을 가질 수 있으나 이에 한정되는 것은 아니다.According to one embodiment of the present invention, the cosmetic composition of the present invention is a softening longevity, nourishing longevity, essence, lotion, nourishing cream, massage cream, pack, gel, ointment, patch, spray, linen, pasta, cataplasma It may have a formulation such as, but is not limited thereto.
또한, 본 발명은 흰무늬엉겅퀴 추출물, 생강 추출물, 유럽승마 추출물, 감초 추출물 및 붉은토끼풀꽃 추출물로 이루어진 군으로부터 선택되는 2종 이상의 식물 추출물을 유효성분으로 함유하는 피부 주름 개선용 약학적 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for improving skin wrinkles containing two or more plant extracts selected from the group consisting of white thistle extract, ginger extract, European horse riding extract, licorice extract and red shamrock extract as an active ingredient do.
또한, 본 발명은 흰무늬엉겅퀴 추출물, 생강 추출물, 유럽승마 추출물, 감초 추출물 및 붉은토끼풀꽃 추출물로 이루어진 군으로부터 선택되는 2종 이상의 식물 추출물을 유효성분으로 함유하는 피부 주름 개선용 건강식품을 제공한다.In addition, the present invention provides a health food for skin wrinkles containing two or more plant extracts selected from the group consisting of white thistle extract, ginger extract, European horse riding extract, licorice extract and red shamrock extract as an active ingredient. .
본 발명의 조성물은 피부의 진피를 구성하는 주요한 단백질인 데코린 및 바이글리칸의 발현을 현저하게 증가시키거나 이들에 결합해 있는 글리코사미노글리칸의 사슬의 길이를 증가시킴으로써 우수한 탄력 증진 및 주름 개선 효과를 가지므로, 피부 주름 및 탄력을 개선하기 위한 조성물로서 유용하게 사용될 수 있다.The composition of the present invention provides excellent elasticity enhancement and wrinkles by significantly increasing the expression of decorin and byglycans, which are the major proteins constituting the dermis of the skin, or by increasing the length of the chain of glycosaminoglycans bound thereto. Since it has an improvement effect, it can be usefully used as a composition for improving skin wrinkles and elasticity.
도 1은 흰무늬엉겅퀴 추출물, 유럽승마 추출물, 생강 추출물 및 감초 추출물을 단독으로 또는 조합하여 처리할 경우, 피부 섬유아세포에서 데코린, 바이글리칸 및 MMP-1의 발현에 미치는 영향을 보여주는 웨스턴 블롯(Western Blot) 전기영동 사진이다.
도 2a는 흰무늬엉겅퀴 추출물 및 붉은토끼풀꽃 추출물을 단독으로 또는 조합하여 처리할 경우, 피부 섬유아세포에서 데코린 및 MMP-1의 발현에 미치는 영향을 보여주는 웨스턴 블롯 전기영동 사진이다.
도 2b는 유럽승마 추출물 및 붉은토끼풀꽃 추출물을 단독으로 또는 조합하여 처리할 경우, 피부 섬유아세포에서 데코린 및 MMP-1의 발현에 미치는 영향을 보여주는 웨스턴 블롯 전기영동 사진이다.
도 3a는 유럽승마 추출물 및 감초 추출물을 단독으로 처리하거나, 유럽승마 추출물에 감초 추출물, 붉은토끼풀꽃 추출물 또는 흰무늬엉겅퀴 추출물을 조합하여 처리할 경우, 인체 피부 도포 실험에서 데코린의 발현에 미치는 영향을 보여주는 웨스턴 블롯 전기영동 사진이다.
도 3b는 흰무늬엉겅퀴 추출물 및 붉은토끼풀꽃 추출물을 단독으로 또는 조합하여 처리하거나, 상기 추출물에 감초 추출물을 함께 처리할 경우, 인체 피부 도포 실험에서 데코린의 발현에 미치는 영향을 보여주는 웨스턴 블롯 전기영동 사진이다.Figure 1 is a Western blot showing the effect on the expression of decorin, baiglican and MMP-1 in skin fibroblasts when treated alone or in combination with white thistle extract, European horse riding extract, ginger extract and licorice extract (Western Blot) Picture of electrophoresis.
Figure 2a is a Western blot electrophoresis picture showing the effect on the expression of decorin and MMP-1 in skin fibroblasts when treated alone or in combination of white thistle extract and red shamrock extract.
Figure 2b is a Western blot electrophoresis picture showing the effect on the expression of decorin and MMP-1 in skin fibroblasts when treated alone or in combination with European horseback riding extract and Red Rabbit flower extract.
Figure 3a is the effect on the expression of decorin in human skin application experiments when the European horseback extract and licorice extracts alone or in combination with licorice extract, red shamrock extract or white thistle extract Western blot electrophoresis showing.
Figure 3b is a Western blot electrophoresis showing the effect on the expression of decorin in human skin application experiments when the white thistle extract and red shamrock extract alone or in combination, or treated with licorice extract to the extract It is a photograph.
본 발명은 흰무늬엉겅퀴 추출물, 생강 추출물, 유럽승마 추출물, 감초 추출물 및 붉은토끼풀꽃 추출물로 이루어진 군으로부터 선택되는 2종 이상의 식물 추출물을 유효성분으로 함유하는 피부 주름 개선용 피부 화장료 조성물을 제공한다.The present invention provides a skin cosmetic composition for improving skin wrinkles containing two or more plant extracts selected from the group consisting of white thistle extract, ginger extract, European horse riding extract, licorice extract and red shamrock extract as an active ingredient.
본 발명에서 일컫는 "추출물"은 식물 원료로부터 임의의 방법으로 추출된 물질을 나타내는 것으로서, 이렇게 추출된 추출액, 이로부터 얻을 수 있는 농축액, 상기 농축액의 건조물, 분말, 또는 상기 추출액의 발효물 등을 제한 없이 모두 포함하는 의미로 사용된다. 상기 추출물은 식물 원료 또는 이의 건조물로부터 추출하여 얻을 수 있으며, 상기 추출물의 원료는 재배한 것 또는 시판되는 것 등을 제한 없이 사용할 수 있다.As used herein, the term "extract" refers to a material extracted from a plant raw material by any method, and limits the extract thus extracted, the concentrate obtained therefrom, the dried product of the concentrate, powder, or the fermentation product of the extract. It is used to include all without. The extract can be obtained by extracting from a plant raw material or its dried material, the raw material of the extract can be used without limitation, such as cultivated or commercially available.
본 발명의 조성물에 포함되는 흰무늬엉겅퀴 추출물은 실리마린(Silymarin)이라고 불리는 플라보노이드 복합체가 주요성분으로 알려져 있으며, 간 보호 효과, 항산화 효과, 엘라스타제 억제 효과 등이 잘 알려져 있어 생약으로 사용되고 있다. 본 발명의 한 구현예에 따르면, 흰무늬엉겅퀴 추출물은 섬유아세포 배양 실험에서 데코린, 바이글리칸과 같은 프로테오글리칸의 발현양과 글리코사미노글리칸의 사슬 길이를 증가시키는 효과가 있으므로, 피부 주름 개선뿐만 아니라 피부 노화의 개선에도 효과가 있을 가능성이 있다.White patterned thistle extract included in the composition of the present invention is known as the main component of the flavonoid complex called silymarin (Silymarin), liver protection effect, antioxidant effect, elastase inhibitory effect is well known and is used as a herbal medicine. According to one embodiment of the present invention, white patterned thistle extract has an effect of increasing the expression of proteoglycans and chain lengths of glycosaminoglycans such as decorin and biglycans in fibroblast culture experiments, thereby improving skin wrinkles. In addition, it may be effective in improving skin aging.
본 발명의 조성물에 포함되는 생강 추출물은 쇼가올(Shogaol), 진저롤(Gingerol) 등의 항산화 성분을 포함하고 있다. 본 발명의 한 구현예에 따르면, 생강 추출물은 섬유아세포 배양 실험에서 데코린, 바이글리칸의 글리코사미노글리칸의 사슬의 길이를 증가시키는 효과가 있는 것으로 나타났다.Ginger extract included in the composition of the present invention contains an antioxidant component such as Shogaol, Gingerol. According to one embodiment of the present invention, the ginger extract has been shown to have an effect of increasing the length of the chains of glycosaminoglycans of decorin, biglycans in fibroblast culture experiments.
본 발명의 조성물에 포함되는 유럽승마 추출물은 식물성 여성호르몬 성분을 함유하여 갱년기 증상 치료제로 널리 사용되고 있다. 본 발명의 한 구현예에 따르면, 유럽승마 추출물은 섬유아세포 배양 실험에서 데코린, 바이글리칸의 글리코사미노글리칸의 사슬의 길이를 증가시키는 효과가 있는 것으로 나타났다.European horseriding extract included in the composition of the present invention is widely used as a therapeutic agent for menopausal symptoms by containing a female female hormone component. According to one embodiment of the present invention, the European horseriding extract has been shown to have an effect of increasing the length of the chains of glycosaminoglycans of decorin, baiglican in fibroblast culture experiments.
본 발명의 조성물에 포함되는 감초 추출물은 함유하고 있는 항산화 성분을 통해 자외선에 의한 MMP-1의 발현을 억제하고, 콜라젠의 발현 억제를 회복시키는 등의 항노화 효과가 있는 것이 알려져 있다. 본 발명의 한 구현예에 따르면, 감초 추출물은 섬유아세포 배양 실험에서 데코린, 바이글리칸의 발현양을 증가시키는 효과가 있는 것으로 나타났다.Licorice extract contained in the composition of the present invention is known to have an anti-aging effect such as suppressing the expression of MMP-1 by ultraviolet rays and restoring the expression inhibition of collagen through the antioxidant component contained. According to one embodiment of the present invention, licorice extract has been shown to have an effect of increasing the amount of decorin, biglycan expression in fibroblast culture experiments.
본 발명의 조성물에 포함되는 붉은토끼풀꽃 추출물은 유럽승마추출물과 유사하게 식물성 여성호르몬 성분을 함유하여 갱년기 증상치료제로 널리 사용되고 있으며, 난소가 제거된 랫트의 피부에서 발생하는 표피두께 감소, 글랜드 및 혈관의 부족 등의 현상을 회복시켜줄 수 있는 것으로 알려져 있다. 본 발명의 한 구현예에 따르면, 붉은토끼풀꽃 추출물은 섬유아세포 배양 실험에서 데코린, 바이글리칸의 발현양을 증가시켜주는 효과가 있는 것으로 나타났다.Red rabbit flower extract in the composition of the present invention contains a plant female hormone component similar to the European horse riding extract is widely used as a therapeutic agent for menopausal symptoms, epidermal thickness reduction, gland and It is known to be able to recover from the lack of blood vessels. According to one embodiment of the present invention, the red shamrock flower extract has been shown to have an effect of increasing the amount of decorin, Baiglican expression in fibroblast culture experiments.
상기 식물 추출물을 식물 원료로부터 추출하여 수득할 때, 추출 방법으로는 용매 추출법, 초음파 추출법, 여과법 및 환류 추출법 등과 같이 종래 알려진 통상적인 추출 방법을 비제한적으로 사용할 수 있으며, 바람직하게는 용매 추출법이나 환류 추출법을 이용함으로써 제조할 수 있으나 이에 한정되는 것은 아니다. 상기 추출 과정은 수회 반복할 수 있으며, 이후에 농축 또는 동결건조 등의 단계를 추가적으로 거칠 수 있다. 구체적으로, 수득한 식물 추출물을 감압 농축하여 농축액을 얻고, 상기 농축액을 동결건조시킨 후 분쇄기를 이용하여 고농도의 식물 추출물 분말을 제조할 수 있다.When the plant extract is obtained by extracting it from plant raw materials, conventional extraction methods such as solvent extraction, ultrasonic extraction, filtration and reflux extraction can be used without limitation, and preferably solvent extraction or reflux. It may be prepared by using an extraction method, but is not limited thereto. The extraction process may be repeated several times, after which it may be further subjected to steps such as concentration or lyophilization. Specifically, the obtained plant extract may be concentrated under reduced pressure to obtain a concentrate, and the concentrate may be lyophilized to prepare a high concentration plant extract powder using a grinder.
상기 식물 추출물은 물, 유기용매 또는 이들의 혼합물을 추출용매로 하여 추출될 수 있다. 상기 유기용매는 알코올, 바람직하게는 C1-C4의 알코올, 예컨대 메탄올, 에탄올, 프로판올 또는 부탄올, 헥산(n-헥산), 에테르, 글리세롤, 프로필렌글리콜, 부틸렌글리콜, 에틸아세테이트, 메틸아세테이트, 디클로로메탄, 클로로포름, 벤젠 및 이들의 혼합용매를 사용할 수 있으나 이에 한정되는 것은 아니다.The plant extract may be extracted using water, an organic solvent or a mixture thereof as an extractant. The organic solvent is an alcohol, preferably C 1 -C 4 alcohols such as methanol, ethanol, propanol or butanol, hexane (n-hexane), ether, glycerol, propylene glycol, butylene glycol, ethyl acetate, methyl acetate, Dichloromethane, chloroform, benzene and mixed solvents thereof may be used, but are not limited thereto.
본 발명의 화장료 조성물 내에 2종 이상의 식물 추출물 또는 이로부터 유래되는 화합물이 포함될 때, 해당 식물들을 개별적으로 추출한 추출물을 제조한 후 이를 조합해 사용할 수도 있고, 해당 식물들의 혼합물을 추출하여 사용할 수도 있으나 이에 한정되는 것은 아니다.When two or more kinds of plant extracts or compounds derived therefrom are included in the cosmetic composition of the present invention, the extracts may be prepared by separately extracting the plants and then used in combination, or a mixture of the plants may be used. It is not limited.
상기 추출은 60℃ 내지 100℃의 온도에서 실시될 수 있고, 바람직하게는 65℃ 내지 95℃에서 실시될 수 있으며, 더욱 바람직하게는 70℃ 내지 90℃에서 실시될 수 있으나 이에 한정되는 것은 아니다. 상기 범위를 벗어나서 실시될 경우에는 해당 추출물의 데코린 및 바이글리칸 발현 증가 활성이 낮아질 수 있다.The extraction may be carried out at a temperature of 60 ℃ to 100 ℃, preferably may be carried out at 65 ℃ to 95 ℃, more preferably may be carried out at 70 ℃ to 90 ℃, but is not limited thereto. When carried out outside the range, the activity of increasing the decorin and biglycan expression of the extract may be lowered.
상기 추출은 1시간 내지 20시간 동안 실시될 수 있고, 바람직하게는 2시간 내지 16시간 동안 실시될 수 있으며, 더욱 바람직하게는 3시간 내지 12시간 동안 실시될 수 있으나, 이에 한정하지 아니한다. 상기 범위를 벗어나서 실시될 경우에는 해당 추출물의 데코린 및 바이글리칸 발현 증가 활성이 낮아질 수 있다.The extraction may be carried out for 1 to 20 hours, preferably for 2 to 16 hours, more preferably for 3 to 12 hours, but is not limited thereto. When carried out outside the range, the activity of increasing the decorin and biglycan expression of the extract may be lowered.
상기 추출은 1회 내지 8회 실시될 수 있고, 바람직하게는 1회 내지 6회 실시될 수 있으며, 더욱 바람직하게는 1회 내지 5회 실시될 수 있으나 이에 한정되는 것은 아니다. 상기 추출물은 각 추출에서 얻어진 단독 추출물 또는 각 추출에서 얻어진 추출물들의 혼합 추출물일 수 있고, 바람직하게는 각 추출에서 얻어진 추출물들의 혼합 추출물일 수 있다.The extraction may be performed once to eight times, preferably may be carried out once to six times, more preferably may be carried out once to five times, but is not limited thereto. The extract may be a single extract obtained from each extract or a mixed extract of extracts obtained from each extract, preferably a mixed extract of extracts obtained from each extract.
상기 식물 추출물은 데코린 및 바이글리칸 발현 증가 활성의 효과를 높이기 위하여 추가로 통상의 분획 공정을 수행할 수 있다. 예를 들면, 본 발명에 따른 식물 추출물을 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 통과시켜 얻은 분획물, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등으로 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 활성 분획물도 본 발명의 식물 추출물의 범위 내에 포함된다. 상기 크로마토그래피는 컬럼 크로마토그래피일 수 있고, 예컨대 실리카겔, 세파덱스, LH-20, ODS 겔, RP-18, 폴리아미드, 도요펄(Toyopearl) 및 XAD 수지로 이루어진 군으로부터 선택된 충진제를 이용하는 컬럼 크로마토그래피를 수행하여 활성 분획물을 분리 및 정제할 수 있으며, 컬럼 크로마토그래피는 필요에 따라 적절한 충진제를 선택하여 수차례 실시할 수 있으나 이에 한정되는 것은 아니다. 상기 크로마토그래피를 사용함에 있어 용출 용매, 용출 속도 및 용출 시간은 본 기술분야의 통상의 기술자가 일반적으로 사용하는 용매, 속도 또는 시간 등을 적용할 수 있다.The plant extract may further perform a conventional fractionation process in order to increase the effect of increasing the decorin and biglycan expression. For example, fractions obtained by passing a plant extract according to the present invention through an ultrafiltration membrane having a constant molecular weight cut-off value, separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity). Active fractions obtained through various purification methods additionally carried out in the above are also included within the scope of the plant extracts of the present invention. The chromatography may be column chromatography, for example column chromatography using a filler selected from the group consisting of silica gel, Sephadex, LH-20, ODS gel, RP-18, polyamide, Toyopearl and XAD resin The active fraction can be separated and purified by performing the step, and column chromatography can be carried out several times by selecting an appropriate filler as necessary, but is not limited thereto. In using the chromatography, an elution solvent, an elution rate, and an elution time may be applied to a solvent, a rate, or a time generally used by those skilled in the art.
본 발명의 화장료 조성물은 상기 식물 추출물 이외에 본 발명이 목적으로 하는 효과를 손상시키지 않는 범위 내에서, 바람직하게는 상기 식물 추출물에 상승효과를 줄 수 있는 다른 성분 등을 추가로 함유할 수 있다. 예를 들면, 본 발명의 화장료 조성물은 상기 식물 추출물 이외에도 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제 또는 담체를 비제한적으로 포함할 수 있다. 또한, 본 발명의 화장료 조성물은 상기 식물 추출물 또는 이로부터 유래되는 화합물에 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있고, 안정화제, 수화제 또는 유화 촉진제, 삼투압 조절을 위한 염 및/또는 완충제 등의 보조제를 추가로 함유할 수 있다.The cosmetic composition of the present invention may further contain, in addition to the above-mentioned plant extracts, other ingredients that can give a synergistic effect to the above-mentioned plant extracts within a range that does not impair the effects aimed at by the present invention. For example, the cosmetic composition of the present invention may include, without limitation, conventional adjuvants or carriers such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors in addition to the plant extract. In addition, the cosmetic composition of the present invention may contain one or more active ingredients exhibiting the same or similar functions in addition to the plant extract or a compound derived therefrom, and stabilizers, wetting agents or emulsifiers, salts for controlling osmotic pressure And / or adjuvants such as buffers.
본 발명의 식물 추출물의 함량은 화장료 조성물 총 중량에 대해 0.0001 내지 50 중량%일 수 있고, 바람직하게는 0.01 내지 40중량%일 수 있으며, 보다 바람직하게는 0.1 내지 20 중량%일 수 있고, 더욱 바람직하게는 0.2 내지 10 중량%일 수 있으나 이에 한정되는 것은 아니다. 상기 식물 추출물의 함량이 0.0001 중량% 미만일 경우에는 충분한 데코린 및 바이글리칸 발현 증가 활성을 통한 피부 주름 개선 효과를 얻을 수 없고, 50 중량%를 초과할 경우에는 함유량 증가에 따른 뚜렷한 효능 상승 효과가 떨어지는 문제점이 있다.The content of the plant extract of the present invention may be 0.0001 to 50% by weight, preferably 0.01 to 40% by weight, more preferably 0.1 to 20% by weight, and more preferably, based on the total weight of the cosmetic composition. Preferably it may be 0.2 to 10% by weight, but is not limited thereto. When the content of the plant extract is less than 0.0001% by weight, it is not possible to obtain skin wrinkle improvement through sufficient decorin and biglycan expression increasing activity. There is a problem falling.
본 발명의 한 구현예에 따르면, 본 발명의 화장료 조성물에 포함되는 성분은 유효 성분으로서의 전술한 2종 이상의 식물 추출물 이외에 본 발명이 목적으로 하는 효과를 손상시키지 않는 범위 내에서 화장품 조성물에 통상적으로 이용되는 성분들을 추가로 포함할 수 있으며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함할 수 있다.According to one embodiment of the present invention, the components included in the cosmetic composition of the present invention are commonly used in cosmetic compositions within the range that does not impair the effects desired by the present invention, in addition to the two or more plant extracts described above as active ingredients. And may include additional ingredients such as antioxidants, stabilizers, solubilizers, conventional auxiliaries such as vitamins, pigments and flavors, and carriers.
본 발명의 화장료 조성물은 그 제형에 있어서 특별히 한정되지 않고, 본 기술분야에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 유연화장수, 영양화장수, 에센스, 로션, 영양크림, 마사지크림, 팩, 젤, 연고, 패취, 분무제, 리니먼트제, 파스타아제 또는 카타플라스마제 등의 제형으로 제조될 수 있다. 여기에서, 상기 제형이 연고인 경우에는 식물 추출물 이외에 바셀린 50.0 내지 97.0 중량%, 및 폴리옥시에틸렌올레일-에테르 포스페이트 0.1 내지 5.0 중량%를 함유하도록 제조되며, 유연화장수는 프로필렌글리콜, 글리세린 등의 다가알코올류 1.0 내지 10.0 중량%, 및 폴리에틸렌올레일에테르, 폴리옥시에틸렌 경화피마자유 등의 계면활성제 0.05 내지 2.0 중량%를 함유하도록 제조된다. 영양화장수 및 영양크림은 스쿠알란, 바셀린, 옥틸도데칸올과 같은 오일류 5.0 내지 20.0 중량%, 및 세탄올, 스테아릴알코올, 밀납 등의 왁스성분 3.0 내지 15.0 중량%를 함유하고, 에센스는 글리세린, 프로필렌글리콜 등 다가알코올류 5.0 내지 30.0 중량%를 함유한다. 마사지크림은 유효성분 이외에 유동파라핀, 바셀린, 이소노닐이소노나노에이트 등의 오일을 30.0 내지 70.0 중량% 함유하여 제조되며, 팩은 폴리비닐알코올을 5.0 내지 20.0 중량% 함유하는 필오프(peel off) 팩 또는 일반유화형 화장료에 카올린, 탈크, 산화아연, 이산화티탄 등의 안료가 5.0 내지 30.0 중량% 함유된 워시오프(wash off) 팩으로 제조될 수 있다.The cosmetic composition of the present invention is not particularly limited in its formulation, and may be prepared in any formulation conventionally prepared in the art, for example, softening cream, nutrient cream, essence, lotion, nourishing cream, massage It may be prepared in the form of a cream, pack, gel, ointment, patch, spray, linen, pasta or cataplasma. Here, when the formulation is an ointment, it is prepared to contain 50.0 to 97.0% by weight of petrolatum, and 0.1 to 5.0% by weight of polyoxyethylene oleyl-ether phosphate in addition to the plant extract, and the flexible cosmetic is polyvalent such as propylene glycol, glycerin, etc. It is prepared to contain 1.0 to 10.0% by weight of alcohols and 0.05 to 2.0% by weight of surfactants such as polyethylene oleyl ether and polyoxyethylene hydrogenated castor oil. Nourishing cream and nourishing cream contains 5.0 to 20.0% by weight of oils such as squalane, petrolatum and octyldodecanol, and 3.0 to 15.0% by weight of wax components such as cetanol, stearyl alcohol and beeswax, and the essence is glycerin and propylene. 5.0-30.0 weight% of polyhydric alcohols, such as glycol, are contained. Massage cream is prepared by containing 30.0 to 70.0% by weight of oil, such as liquid paraffin, petrolatum, and isononyl isononanoate, in addition to the active ingredient, and the pack is peeled off containing 5.0 to 20.0% by weight of polyvinyl alcohol. The pack or general emulsion cosmetic may be prepared as a wash off pack containing 5.0 to 30.0% by weight of pigments such as kaolin, talc, zinc oxide and titanium dioxide.
본 발명에서는 종래의 MMP-1과 콜라겐의 조절을 통한 피부노화 개선 전략을 탈피하여, 새로운 표적으로서 프로테오글리칸들인 데코린과 바이글리칸의 양적 증가 및 글리코사미노글리칸 사슬의 길이의 증가를 함께 유발할 수 있는 식물 추출물의 조합을 발굴하였다. 본 발명의 조성물에 포함되는 식물 추출물의 조합은 노화된 피부에서 발생하는 데코린과 바이글리칸의 감소 및 사슬 길이 감소를 회복시켜줄 수 있다. 상기 데코린과 바이글리칸은 콜라겐 섬유 및 탄력 섬유와 상호작용함으로써 구조적인 역할과 보호 측면의 역할을 하는 것으로 알려져 있으므로, 콜라겐 섬유와 탄력 섬유의 감소에도 간접적으로 효과를 나타낼 수 있다. 또한, 본 발명에서 사용된 식물 추출물들의 경우 단독 또는 조합으로 섬유아세포에 처리되었을 때 MMP-1의 발현 감소 효과도 함께 나타내는 경우도 다수 포함되어 있으므로, 이를 통한 상승 효과도 함께 나타날 수 있다.In the present invention, to avoid the skin aging improvement strategy through the regulation of the conventional MMP-1 and collagen, as a new target to induce a quantitative increase of the proteoglycans decorin and biglycan and increase the length of the glycosaminoglycan chain A combination of plant extracts was excavated. Combination of the plant extracts included in the composition of the present invention can restore the decrease in chain length and the decrease in decorin and biglycans occurring in aged skin. The decorin and byglycans are known to play a structural role and a protective role by interacting with collagen fibers and elastic fibers, and thus may indirectly reduce collagen fibers and elastic fibers. In addition, in the case of the plant extracts used in the present invention when treated alone or in combination with fibroblasts, the expression of MMP-1 also includes a large number of cases are included, as well as synergistic effects through it.
본 발명의 식물 추출물을 함유하는 화장료 조성물을 인간의 피부에 도포하는 화장 방법을 수행하면, 자외선에 의해 손상되는 피부기질을 보호, 구체적으로 데코린 및 바이글리칸 발현 증가 활성을 통한 피부 주름 개선 효과를 얻을 수 있다.When the cosmetic method containing the plant extract of the present invention is applied to a human skin, the cosmetic method protects the skin substrates damaged by ultraviolet rays, and in particular, improves skin wrinkles by increasing the expression of decorin and byglycans. Can be obtained.
또한, 본 발명은 흰무늬엉겅퀴 추출물, 생강 추출물, 유럽승마 추출물, 감초 추출물 및 붉은토끼풀꽃 추출물로 이루어진 군으로부터 선택되는 2종 이상의 식물 추출물을 유효성분으로 함유하는 피부 주름 개선용 약학적 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for improving skin wrinkles containing two or more plant extracts selected from the group consisting of white thistle extract, ginger extract, European horse riding extract, licorice extract and red shamrock extract as an active ingredient do.
상기 약학적 조성물에 함유되는 상기 흰무늬엉겅퀴 추출물, 생강 추출물, 유럽승마 추출물, 감초 추출물 및 붉은토끼풀꽃 추출물로 이루어진 군으로부터 선택되는 2종 이상의 식물 추출물의 함량은 약학적 조성물 총 중량에 대해 0.0001 내지 20.0 중량%인 것이 바람직하고, 0.001 내지 1.0 중량%인 것이 더욱 바람직하지만 이에 한정되는 것은 아니다. 상기 식물 추출물의 함량이 0.0001 중량% 미만이면 피부 주름 개선 효과를 얻을 수 없고, 20 중량%를 초과하면 필요 이상의 식물 추출물을 사용하여 경제적이지 못한 문제점이 있다.The content of two or more plant extracts selected from the group consisting of the white thistle extract, ginger extract, European horse riding extract, licorice extract and red shamrock extract contained in the pharmaceutical composition is 0.0001 to the total weight of the pharmaceutical composition. It is preferably 20.0% by weight, more preferably 0.001 to 1.0% by weight, but is not limited thereto. If the content of the plant extract is less than 0.0001% by weight can not obtain a skin wrinkle improvement effect, if it exceeds 20% by weight there is a problem that is not economical using more than the necessary plant extract.
본 발명에 따른 약학적 조성물의 투여 경로는 구강, 정맥내, 근육내, 동맥내, 경피, 피하, 복강내, 비강내, 장관, 국소, 설하 또는 직장이 포함되고, 비경구 투여가 바람직하고, 보다 바람직하게는 도포에 의한 국부투여(topical application) 방식으로 적용된다. 상기 비경구는 피하, 피내, 정맥내, 근육내, 병소내 주사 또는 주입기술을 포함한다.Routes of administration of the pharmaceutical compositions according to the invention include oral, intravenous, intramuscular, intraarterial, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical, sublingual or rectal, parenteral administration is preferred, More preferably, it is applied in a topical application manner by application. The parenteral includes subcutaneous, intradermal, intravenous, intramuscular, intralesional injection or infusion techniques.
본 발명의 약학적 조성물은 상기 식물 추출물에 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다. 상기 조성물은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다.The pharmaceutical composition of the present invention may further contain one or more active ingredients exhibiting the same or similar functions in addition to the plant extract. The composition may be used in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, oral formulations, external preparations, suppositories, and sterile injectable solutions, respectively, according to conventional methods.
경구투여를 위한 고형제제에는 산제, 과립제, 정제, 캡슐제, 연질캅셀제, 환 등이 포함된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제로는 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 멸균된 수용액, 액제, 비수성용제, 현탁제, 에멀젼, 시럽, 좌제, 에어로졸 등의 외용제 및 멸균 주사제제의 형태로 제형화하여 사용될 수 있으며, 바람직하게는 크림, 젤, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 또는 카타플라스마제의 피부 외용 약학적 조성물을 제조하여 사용할 수 있으나, 이에 한정하는 것은 아니다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Solid preparations for oral administration include powders, granules, tablets, capsules, soft capsules, pills and the like. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents, water and liquid paraffin. . Preparations for parenteral administration include powders, granules, tablets, capsules, sterile aqueous solutions, solutions, non-aqueous solutions, suspensions, emulsions, syrups, suppositories, aerosols, etc. It may be used in the form of a formulation, and preferably, an external skin pharmaceutical composition of a cream, a gel, a patch, a spray, an ointment, a warning, a lotion, a linen, a pasta, or a cataplasm may be prepared. It is not limited to this. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
상기 조성물은 방부제, 안정화제, 수화제 또는 유화 촉진제, 삼투압 조절을 위한 염 및/또는 완충제 등의 보조제, 및 기타 치료적으로 유용한 물질을 추가로 함유할 수 있다.The composition may further contain preservatives, stabilizers, hydrating or emulsifying accelerators, auxiliaries such as salts and / or buffers for controlling osmotic pressure, and other therapeutically valuable substances.
본 발명의 약학적 조성물은 개체의 연령, 체중, 일반적인 건강, 성별, 투여시간, 투여 경로, 배출 속도, 약물 배합 및 특정 질환의 중증을 포함한 여러 요인에 따라 다양하게 변할 수 있다.The pharmaceutical compositions of the present invention may vary depending on several factors, including the age, body weight, general health, sex, time of administration, route of administration, rate of release, drug combination and severity of the particular disease of the individual.
본 발명의 약학적 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하게 처방될 수 있다. 본 발명의 약학적 조성물의 투여량은 성인 기준으로 0.001 내지 100 ㎎/㎏ 범위 내이다. 또한 외용제인 경우에는 성인기준으로 1.0 내지 3.0 ㎖의 양으로 1일 1회 내지 5회 도포하여 1개월 이상 계속하는 것이 좋으나, 상기 투여량은 본 발명의 범위를 한정하는 것이 아니다.Suitable dosages of the pharmaceutical compositions of the present invention may vary depending on factors such as the formulation method, mode of administration, age, weight, sex, morbidity, condition of the patient, food, time of administration, route of administration, rate of excretion and response to reaction. Can be. The dosage of the pharmaceutical composition of the present invention is in the range of 0.001 to 100 mg / kg on an adult basis. In addition, in the case of external preparations, it is preferable to apply once to five times a day in an amount of 1.0 to 3.0 ml on an adult basis and continue for more than one month, but the dosage does not limit the scope of the present invention.
본 발명의 약학적 조성물은 단독으로, 또는 수술, 방사선 치료, 호르몬 치료, 화학 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다. The pharmaceutical composition of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormonal therapy, chemotherapy and biological response modifiers.
본 발명의 식물 추출물은 인간 섬유아세포에서 진피를 구성하는 주요 단백질인 데코린 및 바이글리칸의 발현을 현저하게 증가시킬 수 있고, 천연물 유래의 안전한 물질이므로, 피부 주름 개선을 위한 약학적 조성물의 유효성분으로서 유용하게 사용할 수 있다.The plant extract of the present invention can significantly increase the expression of decorin and biglycans, which are the major proteins constituting the dermis in human fibroblasts, and is a safe substance derived from natural products, and thus is effective in improving pharmaceutical compositions for skin wrinkles. It can be usefully used as a component.
아울러, 본 발명은 흰무늬엉겅퀴 추출물, 생강 추출물, 유럽승마 추출물, 감초 추출물 및 붉은토끼풀꽃 추출물로 이루어진 군으로부터 선택되는 2종 이상의 식물 추출물을 유효성분으로 함유하는 피부 주름 개선용 건강식품을 제공한다.In addition, the present invention provides a health food for improving skin wrinkles containing two or more plant extracts selected from the group consisting of white thistle extract, ginger extract, European horse riding extract, licorice extract and red shamrock extract as an active ingredient. .
상기 식물 추출물의 함량은 사용 목적에 따라 적절하게 결정될 수 있다. 상기 건강식품에 함유되는 흰무늬엉겅퀴 추출물, 생강 추출물, 유럽승마 추출물, 감초 추출물 및 붉은토끼풀꽃 추출물로 이루어진 군으로부터 선택되는 2종 이상의 식물 추출물의 함량은 건강식품 총 중량에 대해 0.0001 내지 20.0 중량%인 것이 바람직하고, 0.001 내지 1.0 중량%인 것이 더욱 바람직하지만 이에 한정되는 것은 아니다. 상기 식물 추출물의 함량이 0.0001 중량% 미만이면 피부 주름 개선 효과를 얻을 수 없고, 20 중량%를 초과하면 필요 이상의 양을 사용하여 경제적이지 못하며 조성물의 안정성이 낮아지는 문제점이 있다. 그러나 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 상기 식물 추출물은 상기 범위 이상의 양으로도 사용될 수 있다.The content of the plant extract may be appropriately determined depending on the intended use. The content of two or more plant extracts selected from the group consisting of white patterned thistle extract, ginger extract, European horse riding extract, licorice extract and red shamrock extract contained in the health food is 0.0001 to 20.0 wt% based on the total weight of the health food. It is preferable to be, and it is more preferable that it is 0.001 to 1.0 weight%, but it is not limited to this. If the content of the plant extract is less than 0.0001% by weight can not obtain a skin wrinkle improvement effect, if it exceeds 20% by weight is not economical using more than necessary amount, there is a problem that the stability of the composition is lowered. However, in the case of long-term intake for health and hygiene or health control, the amount may be below the above range, and since there is no problem in terms of safety, the plant extract may be used in an amount above the above range. .
본 발명의 조성물이 건강식품으로 제조되는 경우, 식품 제조시 통상적으로 첨가되는 성분을 포함할 수 있으며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상기 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토오스, 수크로오스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알코올이다. 상기 향미제로는 천연 향미제 타우마틴, 스테비아 추출물 및 합성 향미제를 사용할 수 있다. 예컨대, 본 발명의 건강식품이 드링크제로 제조되는 경우에는 상기 식물 추출물 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 천연 추출액 등이 추가로 포함될 수 있다.When the composition of the present invention is prepared as a health food, it may include ingredients that are commonly added during food preparation, and include, for example, proteins, carbohydrates, fats, nutrients, seasonings and flavoring agents. Examples of such carbohydrates are monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And sugars such as conventional sugars such as polysaccharides such as dextrin, cyclodextrin and the like and xylitol, sorbitol, erythritol. As the flavoring agent, natural flavoring agent taumartin, stevia extract and synthetic flavoring agent may be used. For example, when the health food of the present invention is prepared with a drink, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, natural extracts, etc. may be further included in addition to the plant extract.
상기 건강식품의 종류에는 특별한 제한은 없다. 본 발명의 식물 추출물을 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함하는 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There is no particular limitation on the kind of the health food. Examples of the food to which the plant extract of the present invention may be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, ice cream, various soups, beverages, Tea, drink, alcoholic beverages and vitamin complexes and the like, and includes all of the health food in the conventional sense.
이하, 본 발명을 실시예 및 실험예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail by Examples and Experimental Examples.
단, 하기 실시예 및 실험예는 본 발명을 예시하기 위한 것일 뿐, 본 발명의 내용이 하기 실시예 및 실험예에 의해 한정되는 것은 아니다.However, the following Examples and Experimental Examples are only for illustrating the present invention, and the content of the present invention is not limited by the following Examples and Experimental Examples.
실시예 1. 식물 추출물의 제조Example 1 Preparation of Plant Extract
본 발명의 화장료 조성물의 유효성분으로 포함되는 흰무늬엉겅퀴, 생강, 유럽승마, 감초 및 붉은토끼풀꽃의 추출물을 각각 제조하였다. 이를 위하여, 상기 각각의 식물 원료에 6배의 증류수를 가해 85℃에서 12시간 추출하고 추출액을 여과하여 10℃로 냉각하였다. 잔사에 대해서는 6배의 증류수를 가해 12시간 추출을 3회 추가로 실시하여 추출액을 여과 후 모두 합하여 10℃로 냉각하였다. 냉각이 완료된 추출액을 4℃에서 15분 동안 6,000rpm으로 원심분리하여 침전물을 제거하여 각각의 식물 추출물을 제조하였다.Extracts of white thistle, ginger, European horseback riding, licorice, and red rabbit flower, which are included as an active ingredient of the cosmetic composition of the present invention, were prepared, respectively. To this end, 6 times distilled water was added to each of the plant raw materials, followed by extraction at 85 ° C. for 12 hours, and the extract was filtered and cooled to 10 ° C. For the residue, 6 times distilled water was added, extraction was further performed three times for 12 hours, and the extracts were combined after filtration and cooled to 10 ° C. The cooled extracts were centrifuged at 6,000 rpm for 15 minutes at 4 ° C. to remove precipitates, thereby preparing respective plant extracts.
실험예 1. 식물 추출물의 조합에 따른 데코린, 바이글리칸, MMP-1의 개선 효과Experimental Example 1. Improvement effect of decorin, Baiglican, MMP-1 by the combination of plant extracts
피부 섬유아세포를 10% 우태아 혈청(Fetal Bovine Serum, FBS)을 포함하는 DMEM(Dulbecco's Modified Eagle's Medium) 배지에 세포가 가득 차도록 배양한 후, 0% FBS-DMEM으로 24시간 처리하였다. 신선한 0% FBS-DMEM으로 배지를 교체하면서, 0.2 ㎎/㎖ 농도의 각종 식물 추출물들을 단독으로 또는 조합하여 피부 섬유아세포에 처리하였고, 24시간 후 세포로부터 단백질을 추출하였다. 비히클로는 50% 부틸렌 글리콜을 사용하였다. 추출한 단백질 샘플을 웨스턴 블롯 방법으로 각각의 항체를 이용하여 MMP-1, 바이글리칸, 데코린의 발현 변화를 확인하였으며, 알파튜불린(α-Tubulin)을 대조 단백질로 사용하였다.Dermal fibroblasts were incubated in DMEM (Dulbecco's Modified Eagle's Medium) medium containing 10% Fetal Bovine Serum (FBS) to fill cells, and then treated with 0% FBS-DMEM for 24 hours. While replacing the medium with fresh 0% FBS-DMEM, various plant extracts at 0.2 mg / ml concentrations were treated alone or in combination with skin fibroblasts, and proteins were extracted from the cells after 24 hours. As vehicle, 50% butylene glycol was used. The extracted protein samples were confirmed by Western blot method using the respective antibodies to change the expression of MMP-1, Baiglican, and decorin, and alpha-tubulin was used as a control protein.
웨스턴 블롯을 수행하기 위하여, 상기 추출한 단백질 샘플의 1/3의 부피만큼 4× 라멜리 버퍼를 첨가하여 5분간 끓인 후, 10% SDS-PAGE 젤에 15 ㎕씩 로딩하여 20 mA/gel로 2시간 동안 전기영동하였고, 이를 니트로셀룰로오스 멤브레인에 35 V로 2시간 동안 냉장실에서 트랜스퍼하였다. 트랜스퍼가 완료된 멤브레인은 3% 탈지분유가 함유된 TBS-T 버퍼(Tween 20을 0.05% 함유하는 Tris계 식염수 버퍼)로 1시간 동안 상온에서 블로킹하였고, TBS-T 버퍼로 세척 후 MMP-1, 바이글리칸, 데코린 및 알파튜불린 항체를 각각 1:1,000으로 희석하여 냉장실에서 밤새 반응시켰다. 이를 다시 TBS-T 버퍼로 세척한 후 HRP 효소가 결합된 2차 항체를 1:10,000으로 희석하여 상온에서 1시간 동안 반응시켰고, 다시 TBS-T 버퍼로 세척한 후, 화학발광 용액을 통해 필름에 감광하여 MMP-1, 바이글리칸, 데코린 및 알파튜불린 단백질의 양을 확인하였다.To perform Western blot, add 4 × lamelli buffer to the volume of 1/3 of the extracted protein sample and boil for 5 minutes, load 15 μl into 10% SDS-PAGE gel and 20 mA / gel for 2 hours. Were electrophoresed and transferred to nitrocellulose membrane at 35 V for 2 hours in the refrigerator. Transfer completed membranes were blocked with TBS-T buffer containing 3% skim milk powder (Tris-based saline buffer containing 0.05% of Tween 20) for 1 hour at room temperature, and washed with TBS-T buffer before MMP-1, Glycan, decorin and alphatubulin antibodies were diluted 1: 1,000 each and reacted overnight in the cold room. After washing this again with TBS-T buffer, the secondary antibody conjugated with HRP enzyme was diluted 1: 10,000 and reacted at room temperature for 1 hour. After washing with TBS-T buffer, the film was washed with chemiluminescent solution. Photosensitized to determine the amount of MMP-1, Baiglican, decorin and alphatubulin proteins.
그 결과, 흰무늬엉겅퀴 추출물, 유럽승마 추출물, 생강 추출물 및 감초 추출물을 단독으로 처리한 경우, MMP-1의 발현은 변화가 없거나 감소하였고, 바이글리칸과 데코린은 대체적으로 발현량과 사슬 길이(밴드 위치)가 증가하는 양상을 보였다. 또한, 상기 4종의 식물 추출물을 2종 혼합하여 처리한 경우, MMP-1의 발현은 대체로 크게 감소하였고, 바이글리칸과 데코린은 전체적으로 양적 발현과 사슬 길이 증가가 더욱 촉진되었다(도 1).As a result, when the white thistle extract, European horseback riding extract, ginger extract and licorice extract alone were treated, the expression of MMP-1 was unchanged or decreased. Band position) increased. In addition, when treated by mixing two of the four plant extracts, the expression of MMP-1 was largely reduced significantly, and the total glycemic expression and the increase in the chain length was further promoted as a whole glycine and decorin (Fig. 1) .
또한, 흰무늬엉겅퀴 추출물 및 붉은토끼풀꽃 추출물을 단독으로 처리한 경우, MMP-1의 발현은 변화가 없거나 감소하였고, 데코린은 사슬 길이 또는 발현량이 각각 증가하였다. 상기 흰무늬엉겅퀴 추출물과 붉은토끼풀꽃 추출물을 조합하여 처리한 경우, MMP-1의 발현 감소 효과는 약해졌으나, 데코린의 발현량과 사슬 길이는 함께 증가하였다(도 2a).In addition, when the white thistle extract and Red Rabbit extract alone were treated, the expression of MMP-1 was unchanged or decreased, and decorin increased the chain length or the amount of expression, respectively. When the combination of the white patterned thistle extract and the extract of the red shamrock extract, the effect of reducing the expression of MMP-1 was weakened, but the expression and chain length of the decorin was increased together (Fig. 2a).
아울러, 유럽승마 추출물과 붉은토끼풀꽃 추출물을 단독으로 처리한 경우, MMP-1의 발현은 감소하였고, 데코린은 사슬 길이 또는 발현량이 각각 증가하였다. 상기 유럽승마 추출물과 붉은토끼풀꽃 추출물을 조합하여 처리한 경우, MMP-1의 발현은 현저히 감소하였으며, 데코린은 발현량과 사슬 길이가 함께 증가하였다(도 2b).In addition, the expression of MMP-1 decreased when the European horseback riding extract and Red Rabbit flower extract were treated alone, and the chain length or expression amount of decorin increased, respectively. When the combination of the European horseback riding extract and Red Rabbit flower extract was treated, the expression of MMP-1 was significantly decreased, and the amount of decorin and the chain length were increased together (FIG. 2B).
실험예 2. 인체 피부 도포 실험에서의 식물 추출물들의 조합에 따른 데코린의 개선 효과Experimental Example 2. Improvement effect of decorin according to the combination of plant extracts in human skin application experiment
65세 이상 여성의 엉덩이 피부에 2% 농도의 실시예 1에서 제조한 식물 추출물들을 단독으로 또는 조합하여 12일간 총 3회(1, 5, 9일째) 첩포하였으며, 12일째 조직을 생검하여 단백질을 추출하였다. 식물 추출물 원액의 용매는 50% 부틸렌글리콜이며, 도포한 조성물에는 4%가 포함되었고, 나머지 96%는 부틸렌글리콜 40%, 에탄올 60%를 사용하였다. 1인당 최대 6 부위를 시험에 포함하였고, 추출한 단백질 샘플을 실험예 1에 개시된 것과 같은 웨스턴 블롯 방법으로 각각의 항체를 이용하여 데코린의 발현 변화를 확인하였으며, 베타-액틴(β-actin)과 Ponceau S 염색 결과를 대조단백질로 사용하였다.Plant extracts prepared in Example 1 at 2% concentration alone or in combination were patched three times (
그 결과, 유럽승마 추출물, 감초 추출물, 흰무늬엉겅퀴 추출물 및 붉은토끼풀꽃 추출물을 단독으로 처리한 경우, 데코린은 대체로 발현량과 사슬 길이가 증가하였다. 상기 4종의 식물 추출물을 2종 혼합하여 처리한 경우, 데코린은 발현량과 사슬 길이가 함께 증가하였고, 특히 유럽승마 추출물과 감초 추출물의 조합, 유럽승마 추출물과 흰무늬엉겅퀴 추출물의 조합 및 붉은토끼풀꽃 추출물과 감초 추출물의 조합에서 데코린의 발현량과 바이글리칸의 길이가 더욱 현저히 증가하였다(도 3a 및 도 3b).As a result, when the European horseback extract, licorice extract, white thistle extract, and red shamrock extract alone were treated, decorin generally increased expression and chain length. When two kinds of the above four plant extracts were treated and treated, decorin increased expression and chain length together, in particular, the combination of the European horse riding extract and licorice extract, the combination of the European horse riding extract and the white thistle extract, and the red rabbit. The combination of grass flower extract and licorice extract significantly increased the amount of decorin expression and the length of balycans (FIGS. 3A and 3B).
제조예 1. 화장료 조성물의 제조Preparation Example 1 Preparation of Cosmetic Composition
본 발명의 식물 추출물의 조합을 유효성분으로 함유하는 유연 화장수, 영양크림 및 로션은 각각 하기 표 1 내지 표 3과 같이 제조하였다.Flexible lotion, nourishing cream and lotion containing a combination of the plant extract of the present invention as an active ingredient were prepared as shown in Tables 1 to 3, respectively.
제조예 2. 약학적 조성물의 제조Preparation Example 2 Preparation of Pharmaceutical Composition
<2-1> 피부 외용 연고의 제조<2-1> Preparation of skin ointment
본 발명의 식물 추출물의 조합을 유효성분으로 함유하는 피부 외용 연고를 하기 표 4의 조성과 같이 제조하였다.Skin external ointment containing the combination of the plant extract of the present invention as an active ingredient was prepared as shown in Table 4 below.
<2-2> 피부 외용 패취제의 제조<2-2> Preparation of an external skin patch
본 발명의 식물 추출물의 조합을 유효성분으로 함유하는 피부 외용 패취를 하기 표 5의 조성과 같이 제조하였다.An external skin patch containing the combination of the plant extracts of the present invention as an active ingredient was prepared as shown in Table 5 below.
<2-3> 산제의 제조<2-3> Preparation of powder
붉은토끼풀꽃 추출물 및 감초 추출물············· 2 gRhododendron Extract and Licorice Extract ... ············ 2 g
유당···························· 1 gLactose ································· 1g
상기의 성분을 혼합하고 기밀포에 충진하여 산제를 제조하였다.The above ingredients were mixed and filled in airtight cloth to prepare a powder.
Claims (7)
상기 식물 추출물의 제조에 사용되는 추출용매는 물, 유기용매 및 이들의 혼합물로 이루어진 군으로부터 선택되는 화장료 조성물.The method according to claim 1,
Extraction solvent used in the preparation of the plant extract is selected from the group consisting of water, organic solvents and mixtures thereof.
상기 유기용매는 알코올, 헥산, 에테르, 글리세롤, 프로필렌글리콜, 부틸렌글리콜, 에틸아세테이트, 메틸아세테이트, 디클로로메탄, 클로로포름, 벤젠 및 이들의 혼합용매로 이루어진 군으로부터 선택되는 화장료 조성물.The method according to claim 2,
The organic solvent is selected from the group consisting of alcohol, hexane, ether, glycerol, propylene glycol, butylene glycol, ethyl acetate, methyl acetate, dichloromethane, chloroform, benzene and a mixed solvent thereof.
상기 알코올은 메탄올, 에탄올, 프로판올 및 부탄올로 이루어진 군으로부터 선택되는 화장료 조성물.The method according to claim 3,
The alcohol is a cosmetic composition selected from the group consisting of methanol, ethanol, propanol and butanol.
유연화장수, 영양화장수, 에센스, 로션, 영양크림, 마사지크림, 팩, 젤, 연고, 패취, 분무제, 리니먼트제, 파스타아제 및 카타플라스마제로 이루어진 군으로부터 선택되는 제형을 갖는 화장료 조성물.The method according to claim 1,
A cosmetic composition having a formulation selected from the group consisting of softening cosmetics, nourishing cosmetics, essences, lotions, nourishing creams, massage creams, packs, gels, ointments, patches, sprays, lining agents, pastases and cataplasmas.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180096087A KR102124065B1 (en) | 2018-08-17 | 2018-08-17 | Composition for improving skin wrinkle comprising plant extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180096087A KR102124065B1 (en) | 2018-08-17 | 2018-08-17 | Composition for improving skin wrinkle comprising plant extract |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20200020405A true KR20200020405A (en) | 2020-02-26 |
KR102124065B1 KR102124065B1 (en) | 2020-06-17 |
Family
ID=69637718
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180096087A KR102124065B1 (en) | 2018-08-17 | 2018-08-17 | Composition for improving skin wrinkle comprising plant extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102124065B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220072520A (en) * | 2020-11-25 | 2022-06-02 | 주식회사 네이처센스 | Compositions for inner beauty containing cirsium japonicum extract as effective component |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004508317A (en) * | 2000-06-29 | 2004-03-18 | クイック メド テクノロジーズ インコーポレーティッド | Cosmetic composition and method |
KR20050114677A (en) * | 2003-03-25 | 2005-12-06 | 가부시키가이샤환케루 | Composition for promoting production of type i collagen and/or elastin |
KR20160003918A (en) * | 2014-07-01 | 2016-01-12 | 주식회사 엘지생활건강 | Cosmetic composition for enhancing skin elasticity or improving skin wrinkle containing herb extracts |
KR20170031386A (en) * | 2015-09-11 | 2017-03-21 | 주식회사 비오코스 | Cosmetic Composition Containing the Mixed Extract of Eucalyptus Globulus Leaf and Trifolium Pratense Leaf |
KR20170037570A (en) | 2015-09-25 | 2017-04-04 | 서울대학교산학협력단 | Composition for Preventing Skin Aging and Improving Skin Wrinkle Comprising Extract of Perilla Leaf |
-
2018
- 2018-08-17 KR KR1020180096087A patent/KR102124065B1/en active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004508317A (en) * | 2000-06-29 | 2004-03-18 | クイック メド テクノロジーズ インコーポレーティッド | Cosmetic composition and method |
KR20050114677A (en) * | 2003-03-25 | 2005-12-06 | 가부시키가이샤환케루 | Composition for promoting production of type i collagen and/or elastin |
KR20160003918A (en) * | 2014-07-01 | 2016-01-12 | 주식회사 엘지생활건강 | Cosmetic composition for enhancing skin elasticity or improving skin wrinkle containing herb extracts |
KR20170031386A (en) * | 2015-09-11 | 2017-03-21 | 주식회사 비오코스 | Cosmetic Composition Containing the Mixed Extract of Eucalyptus Globulus Leaf and Trifolium Pratense Leaf |
KR20170037570A (en) | 2015-09-25 | 2017-04-04 | 서울대학교산학협력단 | Composition for Preventing Skin Aging and Improving Skin Wrinkle Comprising Extract of Perilla Leaf |
Non-Patent Citations (2)
Title |
---|
[네이버블로그]주름개선화장품,정진호이펙트 W 에센스 크림 리뷰 (https://blog.naver.com/marketing12/221213582006) (2018.02.21.) 1부.* * |
Fisher G.J. et al., Photochem. Photobiol., 69, 154, 1999 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220072520A (en) * | 2020-11-25 | 2022-06-02 | 주식회사 네이처센스 | Compositions for inner beauty containing cirsium japonicum extract as effective component |
Also Published As
Publication number | Publication date |
---|---|
KR102124065B1 (en) | 2020-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9603789B2 (en) | Composition containing a natural extract | |
KR101971837B1 (en) | Cosmetic composition for improving skin whitening and wrinkle comprising adventitious root extract of Centella asiatica as effective component | |
US9149665B2 (en) | Method and composition for reducing appearance of wrinkles | |
KR101503123B1 (en) | Composition For Preventing Skin Aging and Improving Skin Wrinkle | |
KR101651833B1 (en) | Composition for preventing hair loss or promoting hair growth comprising extract of citrus preicarp | |
US11654169B2 (en) | Methods for protecting skin and/or promoting wound healing | |
KR101851284B1 (en) | Composition for Preventing Skin Aging and Improving Skin Wrinkle Comprising Extract of Perilla Leaf | |
KR20150059551A (en) | Composition for improving skin conditions comprising panax ginseng sprout extract or fraction thereof and method for improving skin conditions using the same | |
KR102130571B1 (en) | Low irritating cosmetic composition for skin whitening comprising albutin and extract of Euterpe oleracea fruit | |
KR101419464B1 (en) | The composition comprising the extract or fraction of Pleurotus eryngii var. ferulae for prevention of anti aging as an active ingredient | |
KR101402565B1 (en) | Composition For Preventing Skin Aging and Improving Skin Wrinkle | |
KR102124065B1 (en) | Composition for improving skin wrinkle comprising plant extract | |
KR101768626B1 (en) | Skin whitening composition comprising an extract obtained from carthamus tinctorius l. | |
KR102462347B1 (en) | Cosmetic composition for improving skin barrier function and anti-wrinkle effects comprising fermented eggplant extract as an active ingredient | |
KR102577528B1 (en) | Composition for improving skin | |
KR20150113632A (en) | Composition for improving skin conditions and method for improving skin conditions using the same | |
KR101579500B1 (en) | Skin whitening composition comprising an extract obtained from roots of coix lachryma-jobi var. mayuen | |
KR20180060611A (en) | Composition for improving skin | |
JP6076719B2 (en) | CGRP response promoter | |
KR101797567B1 (en) | Composition for preventing or improving of skin wrinkle comprising a extracts or fractions of Euphorbia maculata or Euphorbia supina | |
KR20190089748A (en) | A composition for skin whitening comprising Cimicifuga dahurica extract or a fraction thereof | |
KR20130135133A (en) | Pharmaceutical composition containing aleurites fordii extract, fractions thereof or diterpene compound isolated from the fraction for anti-aging | |
KR101747499B1 (en) | Composition for preventing skin aging, treating wrinkled skin, preventing and treating dermatitis comprising lindera sericea extract | |
KR102014685B1 (en) | Compound from Caragana sinica and composition for skin whitening comprising the same | |
KR102475143B1 (en) | Composition for Skin Regeneration Comprising Extract of Vanilla Bean |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |